Pharmacy Drugs
Recent Posts
- Experimental MS Drug Withdrawn From Trial
- Over 50 Pharmacists Trained Up For NPA’s Seasonal Flu Vaccination Service
- The Minister For Health&Children Commences The Outstanding Sections Of The Pharmacy Act 2007 Dealing With Complaints, Inquires And Discipline, Ireland
- Foresight Biotherapeutics Announces Initiation Of Viral Conjunctivitis Clinical Trial
- Study Of Pulmonary Hypertension Treatment In Sickle Cell Patients Halted By NHLBI
Random Posts
- New Anti-Rejection Drug Effective And More Affordable
- AFP Examines Recent HIV Vaccine Findings
- Chemical In Blood May Explain Susceptibility To Bladder Pain
- SPIRIT IV Results Reaffirm Strong Performance Of Boston Scientific PROMUS(R) And TAXUS(R) Express(R) Stents
- Jazz Pharmaceuticals And UCB Announce Second Phase III Study Of Sodium Oxybate In Patients With Fibromyalgia Meets Primary Endpoints
- Spicing Up The Effectiveness Of A Potential Disease-Fighter
- The Medicines Company's Full Analysis Of CHAMPION Phase III Data Shows Cangrelor Significantly Improves Patient Outcomes Following PCI
- Early Cardiovascular Risk Revealed By Vioxx Trial Data
- Medtronic Issues Pacemaker Recall
- National Pharmacy Benefit Manager To Strengthen How It Provides Language Assistance Services
Prices Of Medicines Hit All-time Low, UK
Posted by: admin in Pharmacy Drugs on March 23rd, 2010
The UK has dropped to bottom of the official league table comparing the price of medicines
across Europe, a Government report has revealed.
For the first time, the UK lags behind Austria, Belgium, Finland, France, Germany, Ireland,
Italy, Netherlands, Spain and Sweden.
The figures are published in an annual report to Parliament from the Department of Health,
which sets the price paid for medicines by the NHS. The report compares the 2008 prices of
the leading 150 branded medicines in 11 European countries, the USA and Australia.
The UK ranks 12 out of 13, behind the USA and all of its counterparts in Europe, with only
Australia, a new addition to the list in 2007, coming out lower.
Since 2008, prices have dropped further relative to Europe as there was a cut in January
2009 and Sterling has fallen against the Euro.
Recent analysis by the Association of the British Pharmaceutical Industry (ABPI) puts the UK
behind even Australia in the second quarter of 2009.
David Fisher, commercial director of the ABPI, said: “What we are talking about here is the
breakthrough medicines which make huge differences to people’s lives. Prices in the UK are
less than in any other comparative European country, yet the UK Government, via NICE,
continues to tell patients we can’t afford new medicines.
“I think patients, many of whom have paid into the healthcare pot for many years, should be
asking hard questions about why they are not being allowed to get their investment back.”
Additional research by the ABPI shows that the UK spends one per cent of GDP on
medicines, less than half that of Greece (2.32 per cent) and Portugal (2.17 per cent), half that
of France (2 per cent) and two-thirds of the average of 15 European countries (1.54 per cent).
David Fisher added: “Spending by GDP provides an indication of what is affordable. No
matter what measure you use, the UK is the poor man of Europe. Patients in the UK deserve
better.”
The report to Parliament, published yesterday (Monday Dec 14), also the highlights the
important contribution the pharmaceutical industry makes to the UK economy, with a positive
trade balance of £6.2bn in 2008.
Notes
1) Under the Department of Health’s pricing regime (the PPRS), the price paid for branded
medicines in the UK was cut by seven per cent in January 2005 and 3.9 per cent in January
2009. Another price cut of 1.9 per cent is due to be introduced in 2010. Each percentage point
cut saves the NHS roughly £80m.
2) According to previous Department of Health figures, out of every £1 spent on the NHS, 12p
is spent on medicines.
Source
ABPI
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.